Kitov’s Norvasc-Celebrex Combination Concludes Bioequivalence Study

Kitov Pharmaceuticals successfully completed a second bioequivalence study comparing its combination drug KIT-302 to off-the-shelf Norvasc (amlodipine) and Celebrex (celecoxib).

The study evaluated KIT-302 using a 2.5 mg dose of amlodipine and a 200 mg of celecoxib. A previous bioequivalence study evaluated a 10 mg dose of amlodipine earlier this year.

Norvasc is used to treat chest pain and high blood pressure, and Celebrex is indicated for osteoarthritis pain. Kitov plans to use the study data to support an FDA application.